Strober , B., Asahina, A., Mrowietz, U., Lebwohl, M., Foley, P., Langley, R., Barker, J., Cioffi, C., Cross, N., Wang, M. and Paul, C. 2021. Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial. SKIN The Journal of Cutaneous Medicine. 5, 6 (Nov. 2021), s52. DOI:https://doi.org/10.25251/skin.5.supp.52.